The FDA released a draft guidance document that provides a regulatory framework for sponsors to utilize minimal residual ...

A second protocol defined interim analysis is planned when approximately 50% (or 55) HBeAg+ participants complete 24 weeks of the treatment period. This enrollment milestone occurred in January 2026.

Machine learning models are designed to analyze large, heterogeneous datasets and identify complex relationships without ...

A first-in-human pilot trial suggests umbilical cord–derived mesenchymal stem cell eye drops may safely improve symptoms and inflammation in refractory dry eye, including Sjögren’s syndrome.

Important deadlines include February 1 and March 1, 2026, for abstract submissions, and April 12, 2026, for early-bird ...

Galea, H. , Perry, M. and Jones, P. (2026) Characterising Irritable Bowel Syndrome: An Exploratory Cross-Sectional Study .

The novel oral selective estrogen receptor (ER) degrader giredestrant significantly reduced the risk of invasive disease ...

After a short delay and concerns of potential intervention from senior officials, the FDA has issued a draft guidance for the industry on the potential use of minimal residual disease (MRD) and ...

Women usually shake off gender-linked self-doubt over time, but anxiety-induced insecurities tend to grow with reflection. In ...

Moderna & Merck announce 5-year data for intismeran autogene in combo with Keytruda demonstrated sustained improvement in primary endpoint of recurrence-free survival in patients with high-risk stage ...

‘Consuming an unprocessed diet reduces energy intake: A post-hoc analysis of an RCT reveals a role for human ‘nutritional intelligence’’ by Jeffrey M. Brunstrom et al. was published in The American ...